JP2023506452A5 - - Google Patents

Info

Publication number
JP2023506452A5
JP2023506452A5 JP2022535518A JP2022535518A JP2023506452A5 JP 2023506452 A5 JP2023506452 A5 JP 2023506452A5 JP 2022535518 A JP2022535518 A JP 2022535518A JP 2022535518 A JP2022535518 A JP 2022535518A JP 2023506452 A5 JP2023506452 A5 JP 2023506452A5
Authority
JP
Japan
Prior art keywords
domain
antibody
seq
fusion protein
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022535518A
Other languages
English (en)
Japanese (ja)
Other versions
JP7807076B2 (ja
JP2023506452A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/064515 external-priority patent/WO2021119429A1/en
Publication of JP2023506452A publication Critical patent/JP2023506452A/ja
Publication of JP2023506452A5 publication Critical patent/JP2023506452A5/ja
Application granted granted Critical
Publication of JP7807076B2 publication Critical patent/JP7807076B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022535518A 2019-12-13 2020-12-11 新規インターロイキン-15(il-15)融合タンパク質およびその使用 Active JP7807076B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962947686P 2019-12-13 2019-12-13
US62/947,686 2019-12-13
PCT/US2020/064515 WO2021119429A1 (en) 2019-12-13 2020-12-11 Novel interleukin-15 (il-15) fusion proteins and uses thereof

Publications (3)

Publication Number Publication Date
JP2023506452A JP2023506452A (ja) 2023-02-16
JP2023506452A5 true JP2023506452A5 (cg-RX-API-DMAC7.html) 2023-12-19
JP7807076B2 JP7807076B2 (ja) 2026-01-27

Family

ID=76330576

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022535518A Active JP7807076B2 (ja) 2019-12-13 2020-12-11 新規インターロイキン-15(il-15)融合タンパク質およびその使用

Country Status (8)

Country Link
US (1) US20230048046A1 (cg-RX-API-DMAC7.html)
EP (2) EP4461750A3 (cg-RX-API-DMAC7.html)
JP (1) JP7807076B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220114063A (cg-RX-API-DMAC7.html)
CN (1) CN115087464B (cg-RX-API-DMAC7.html)
AU (1) AU2020402097A1 (cg-RX-API-DMAC7.html)
CA (1) CA3164337A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021119429A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CA3097625A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
WO2019204646A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
CN113286812B (zh) 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
US11618776B2 (en) 2018-12-20 2023-04-04 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
CN111423510B (zh) * 2019-01-10 2024-02-06 迈威(上海)生物科技股份有限公司 重组抗人pd-1抗体及其应用
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
WO2022012428A1 (zh) * 2020-07-14 2022-01-20 迈威(上海)生物科技股份有限公司 抗pd-1抗体及其稳定制剂
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
CN116655771A (zh) * 2021-05-28 2023-08-29 苏州复融生物技术有限公司 一种新型白介素15突变体多肽的开发及其应用
WO2023280307A1 (en) * 2021-07-09 2023-01-12 Nanjing Legend Biotech Co., Ltd. Mutant il-15 compositions and methods thereof
KR20230044131A (ko) * 2021-09-24 2023-04-03 바이오엔시스템스 주식회사 Pd-1 및 il-15를 포함하는 융합단백질 이량체 및 이의 용도
WO2023060156A2 (en) * 2021-10-08 2023-04-13 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
WO2023133424A2 (en) * 2022-01-05 2023-07-13 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides
WO2023160721A1 (en) * 2022-02-28 2023-08-31 Wuxi Biologics (Shanghai) Co., Ltd. Heterodimeric polypeptide complexes comprising il-15 variants and uses thereof
US20240025968A1 (en) * 2022-04-07 2024-01-25 Xencor, Inc. LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS
CN116854821A (zh) * 2022-08-15 2023-10-10 海徕科(北京)生物技术有限公司 IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途
WO2024054425A1 (en) * 2022-09-08 2024-03-14 Cugene Inc. Novel pd1-targeted il-15 immunocytokine and vitokine fusions
CN116063512B (zh) * 2022-10-13 2025-11-07 深圳市百士通科技开发有限公司 多功能重组抗体及其制备方法和应用
KR20250135294A (ko) * 2023-02-21 2025-09-12 레메젠 코, 리미티드 암을 위한 il-15 작용제
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
WO2025252855A1 (en) * 2024-06-05 2025-12-11 Institut National de la Santé et de la Recherche Médicale IL-15 MUTEINS WITH PH-DEPENDENT BINDING FOR IL-15Rbeta
CN118995825B (zh) * 2024-10-24 2025-02-07 星奕昂(上海)生物科技有限公司 一种特异性定量标定白细胞介素15活性的细胞系及其应用
CN121362261A (zh) * 2025-10-30 2026-01-20 北京再青生物科技有限公司 一种靶向T细胞及Her2的双特异性抗体并串联IL-15及其受体的融合蛋白及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
KR20050049545A (ko) * 2002-10-14 2005-05-25 에프. 호프만-라 로슈 아게 길항제 il-15
DK1585548T3 (en) 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
AR069747A1 (es) 2007-11-30 2010-02-17 Medarex Inc Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
AU2009298131B2 (en) * 2008-10-02 2016-07-14 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins
CA2769473A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CN103079644B (zh) 2010-06-11 2017-02-15 协和发酵麒麟株式会社 抗tim‑3抗体
US20150359853A1 (en) * 2012-10-24 2015-12-17 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
EP3093295B1 (en) * 2014-01-08 2020-05-27 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-15 heterogeneous dimer protein and uses thereof
US10858452B2 (en) * 2015-09-16 2020-12-08 Insitut National de la Sante et de la Recherche Medicale (INSERM) Specific interleukin-15 (IL-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases
US10975155B2 (en) * 2016-05-13 2021-04-13 Medimmune, Llc CD40L-Fc fusion polypeptides and methods of use thereof
MX2019004327A (es) * 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
AU2018291497A1 (en) * 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
JP7386161B2 (ja) * 2017-12-19 2023-11-24 ブレイズ バイオサイエンス, インコーポレイテッド 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
AU2019224159B2 (en) * 2018-02-26 2025-05-29 Sanofi IL-15 conjugates and uses thereof
CA3090407A1 (en) * 2018-03-01 2019-09-06 Glycotope Gmbh Fusion protein constructs comprising an anti-muc1 antibody and il-15
CA3097625A1 (en) * 2018-04-18 2019-10-24 Xencor, Inc. Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
CN121086085A (zh) * 2018-06-22 2025-12-09 科优基因公司 新型白介素-15 (il-15)融合蛋白及其用途
CA3116188A1 (en) * 2018-10-12 2020-04-16 Xencor, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
AU2020403148A1 (en) * 2019-12-13 2022-06-30 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof

Similar Documents

Publication Publication Date Title
JP2022536345A5 (cg-RX-API-DMAC7.html)
JP6618463B2 (ja) 三量体型抗原結合分子
RU2015144098A (ru) Четырехвалентные биспецифические антитела
CN107922486B (zh) 异源二聚体多特异性抗体形式
JP2025065142A5 (cg-RX-API-DMAC7.html)
JP2022513116A5 (cg-RX-API-DMAC7.html)
JP2022105574A (ja) 多重特異性分子
EP3253795B1 (en) Novel binding proteins comprising a ubiquitin mutein and antibodies or antibody fragments
JP2019524693A5 (cg-RX-API-DMAC7.html)
JP2022536347A5 (cg-RX-API-DMAC7.html)
JP2019528077A5 (cg-RX-API-DMAC7.html)
JP2021515806A (ja) 三重特異性抗原結合タンパク質
RU2018142544A (ru) Биспецифические связывающие белки и пути их применения
RU2017129591A (ru) МАт-НАПРАВЛЯЕМЫЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРНЫЕ СИСТЕМЫ ДЛЯ СОРТИРОВКИ/ИСТОЩЕНИЯ СКОНСТРУИРОВАННЫХ ИММУННЫХ КЛЕТОК
JP2019531704A5 (cg-RX-API-DMAC7.html)
JP2024023228A5 (cg-RX-API-DMAC7.html)
RU2015129640A (ru) Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1
JP2017521998A (ja) 新規多重特異性分子及びかかる多重特異性分子に基づく新規治療方法
RS56879B1 (sr) Bispecifične molekule koje vezuju antigen za aktiviranje t ćelija
RU2018104703A (ru) Опухолеспецифичное антитело против egfr и его применение
JP2022009816A5 (cg-RX-API-DMAC7.html)
JP2024509910A5 (cg-RX-API-DMAC7.html)
CN115605513A (zh) 一种抗pd-l1和her2的双特异性抗体
JP2024527020A5 (cg-RX-API-DMAC7.html)
CN120548192A (zh) 免疫缀合物